PARP inhibitor improves overall response rates in small cell lung cancer patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a randomized, phase II trial led by researchers at MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates in patients with small cell lung cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login